文献速递糖尿病肥胖与代谢综合征

司美格鲁肽联合或不联合盐皮质激素受体拮抗剂对2型糖尿病合并慢性肾脏病参与者的影响:FLOW试验预设二次分析

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
PubMed 文献 · Diabetes Care · 2025-01-01

FLOW试验预设二次分析评估基线使用盐皮质激素受体拮抗剂(MRA)对司美格鲁肽疗效的影响。参与者随机接受每周一次皮下司美格鲁肽1.0 mg或安慰剂。结果显示,无论基线是否使用MRA,司美格鲁肽对主要肾脏结局、主要不良心血管事件(MACE)和全因死亡率的获益一致。

要点

  • 基线使用MRA者257例,未使用MRA者3276例。
  • 司美格鲁肽降低主要肾脏结局风险:MRA使用者HR 0.51,非使用者HR 0.79,交互P=0.12。
  • MACE和全因死亡率在两组间无异质性(交互P>0.7),安全性相似。

核心结论

  • 在2型糖尿病合并慢性肾脏病参与者中,无论基线是否使用MRA,司美格鲁肽对主要肾脏结局、MACE和全因死亡率均观察到一致的获益。

研究设计与样本

  • FLOW试验的预设二次分析,参与者随机接受每周一次皮下司美格鲁肽1.0 mg或安慰剂。
  • 按基线MRA使用情况分组:使用MRA者257例(司美格鲁肽组136例,安慰剂组121例),未使用MRA者3276例(司美格鲁肽组1631例,安慰剂组1645例)。
  • 基线MRA以螺内酯为主;非奈利酮在招募结束后才可用。

主要发现

  • 司美格鲁肽 vs 安慰剂降低主要肾脏结局风险:MRA使用者49%(59个事件;HR 0.51 [95% CI 0.30, 0.86]),非使用者21%(682个事件;HR 0.79 [95% CI 0.68, 0.92];交互P=0.12)。
  • MACE和全因死亡率在MRA两个亚组间无异质性(交互P>0.7),均支持司美格鲁肽的效应。
  • 第104周白蛋白尿较基线变化:MRA使用者司美格鲁肽组降低15%(95% CI -41, 31),非使用者降低33%(26, 39),vs 安慰剂(交互P=0.22)。
  • 估算肾小球滤过率下降在司美格鲁肽组同样降低(交互P=0.71)。
  • 司美格鲁肽的安全性特征在亚组间相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial, semaglutide reduced the risk of major kidney and cardiovascular (CV) outcomes and all-cause mortality in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). This prespecified analysis assessed the effects of semaglutide on kidney, CV, and mortality outcomes by baseline mineralocorticoid receptor antagonist (MRA) use. RESEARCH DESIGN AND METHODS: Participants were randomized to once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary kidney outcome was a composite of time to first persistent ≥50% eGFR reduction from baseline, kidney failure, or death from kidney/CV causes. Baseline MRA was predominantly spironolactone; finerenone was only available after recruitment ended. RESULTS: Effects were analyzed by baseline MRA use (n = 257 [136 in the semaglutide group and 121 in the placebo group]) and nonuse (n = 3,276 [1,631 in the semaglutide group and 1,645 in the placebo group]). Semaglutide reduced the risk of the primary kidney outcome by 49% (59 events; hazard ratio [HR] 0.51 [95% CI 0.30, 0.86]) and 21% (682 events; HR 0.79 [95% CI 0.68, 0.92]; P-interaction = 0.12) versus placebo in MRA and non-MRA subgroups, respectively. There was no heterogeneity, favoring the effects of semaglutide on major adverse CV events (MACE) and all-cause mortality in both MRA subgroups (P-interaction > 0.7). Albuminuria at 104 weeks was reduced from baseline with semaglutide by 15% (95% CI -41, 31) in MRA users and 33% (26, 39) in nonusers versus placebo (P-interaction = 0.22). Estimated glomerular filtration rate decline was similarly reduced with semaglutide (P-interaction = 0.71). The safety profile of semaglutide was comparable between subgroups. CONCLUSIONS: In participants with T2D and CKD, consistent benefits of semaglutide on major kidney outcomes, MACE, and all-cause mortality were observed regardless of baseline MRA use.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rossing P, Bakris G, Perkovic V, et al. Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis. Diabetes Care. 2025. PMID: 40730031. doi:10.2337/dc25-0472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。